BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end cl ...

BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end cli ...

Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. That was in contrast with the S&P 500 index, which increased by 0.9%.New day, new dealWell before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Ev ...

Topic 1: Financial Performance - [Key Point 1] Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region. [1] - [Key Point 2] Net profit margin improved to 12%, up from 10% in the previous quarter. [2] - [Key Point 3] Operating expenses rose by 8%, primarily due to increased marketing and R&D investments. [3] Topic 2: Market Expansion - [Key Point 1] The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales. [1] - [Key Point 2] A new distribution center was opened in South America to support regional growth. [4] - [Key Point 3] Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration. [2] Topic 3: Product Development - [Key Point 1] Launched three new products in the tech segment, which accounted for 25% of total revenue. [3] - [Key Point 2] R&D investment increased by 10% to accelerate innovation in the healthcare sector. [4] - [Key Point 3] A new line of eco-friendly products was introduced, receiving positive customer feedback. [1] Topic 4: Operational Efficiency - [Key Point 1] Implemented a new ERP system, reducing operational costs by 5%. [2] - [Key Point 2] Streamlined supply chain processes, resulting in a 10% reduction in delivery times. [3] - [Key Point 3] Enhanced inventory management, leading to a 15% decrease in stockouts. [4] Topic 5: Corporate Social Responsibility - [Key Point 1] The company achieved a 30% reduction in carbon emissions through sustainable practices. [1] - [Key Point 2] Launched a community outreach program, benefiting over 10,000 individuals in underserved areas. [2] - [Key Point 3] Increased diversity in the workforce, with women now representing 40% of leadership roles. [3] Topic 6: Future Outlook - [Key Point 1] The company plans to expand its digital transformation initiatives, aiming for a 20% increase in online sales. [4] - [Key Point 2] A new product line is expected to be launched in Q4, targeting the premium segment. [1] - [Key Point 3] The company is exploring opportunities in the renewable energy sector to diversify its portfolio. [2]

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January ...

Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call on January 13, 2025, at 8:30 AM EST BEDFORD, Mass., Ja ...

Acquisition Overview - Lantheus Holdings Inc announced a definitive agreement to acquire Life Molecular Imaging Ltd in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments [1] - The transaction is expected to close in the second half of 2025, subject to customary closing conditions including regulatory approvals [6] - The acquisition is expected to be accretive to Lantheus' Adjusted Earnings Per Share within 12 months of close [2] Strategic Rationale - The acquisition establishes a commercial Alzheimer's disease (AD) franchise with the addition of Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease [1][2] - Life Molecular brings robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development and commercialization of the combined company's pipeline [2] - The acquisition complements Lantheus' pipeline with the addition of highly complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs [4] Financial Impact - The transaction is expected to immediately enhance Lantheus' near and long-term growth profile [2] - Lantheus expects to maximize access to Neuraceq for the approximately 55 million people around the world who are living with AD or mild cognitive impairment [4] - The acquisition builds on Lantheus' June 2024 acquisition of the global rights to LMI's clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers [5] Product Details - Neuraceq is indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline [13] - The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects, with no serious adverse reactions reported [10] - Neuraceq is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea, and Taiwan [20] Company Background - Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes [15] - Life Molecular Imaging is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases [19] - Life Healthcare, the parent company of Life Molecular, is a global people-centered, diversified healthcare organization with over 40 years' experience in the South African private healthcare sector [11]

Short-term market predictions are fun, but rarely worth investing in. Here are two stocks we think will be winners no matter what happens with the market in 2025.In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%).*Stock prices used were from the afternoon of Dec. 18, 2024. The video was publis ...

This is a complementary article on my previous piece about Henry Schein (NASDAQ: HSIC ) which can be found here . That research stemmed from a screen of midcap stocks that led to the following six companies. In my effort toI am a conservative yet opportunistic value investor who has been investing since 2005. I am fact-driven, preferring to let financial data inform me of a company's health, followed by qualitative analysis to fill in the gaps to paint a holistic picture of a company's growth prospects.My w ...

The stock of radiopharmaceutical specialist Lantheus Holdings (LNTH 8.84%) was a standout in the healthcare sector on Hump Day. The company saw its share price improve by almost 9% at market close, thanks to news of a shareholder-pleasing move. That gain far outpaced the S&P 500 index, which ended up closing flat on the day.A $250 million moveWell before market open, Lantheus announced the launch of a $250 million share repurchase program. The initiative will be in force for one year. As is typical for stoc ...